Enavogliflozin
Enavogliflozin is a selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity. It was developed by GC Pharma and Daewoong Pharmaceutical.
Enavogliflozin has been approved for clinical use in South Korea, and Ecuador, and applied for approval in Brazil, Mexico, Peru, and Colombia.